As promised, Amgen Inc. began dosing patients in two pivotal Phase III trials of AMG 162, its fully human monoclonal antibody designed to treat post-menopausal osteoporosis (PMO) and treatment-induced bone loss. (BioWorld Today)
With a plan to boost the efficacy of antibiotics against particularly deadly and resistant bacterial pathogens, Mpex Pharmaceuticals Inc. licensed rights to Trine Pharmaceuticals Inc.'s patents pertaining to efflux pump inhibitors (EPIs) for undisclosed terms. (BioWorld Today)
As the hippies used to remark, it's a gas."It," in this case, is nitric oxide, often called by the forbidding acronym NO, which first gained public acclaim when its key role in erectile function was figured out - leading boatloads of aging flower children (and others) to say "yes" to Viagra, the potency blockbuster generically known as sildenafil citrate that works by inhibiting NO's breakdown in the body.
Although going about the typical process for a biotechnology firm backward, Avera Pharmaceuticals Inc. proved it can make the model work, raising $48 million in a Series C round of venture capital funding. (BioWorld Today)
Gilead Sciences Inc. walloped forecasts by posting second-quarter net income that was up 11 percent, thanks to the briskly selling HIV treatment Viread and the hepatitis B therapy Hepsera. (BioWorld Today)
